WEDNESDAY May 25, 2022
COVID-19 may make a comeback after an infected person goes through a round of Paxlovid, the antiviral used to minimize a bout with the coronavirus, according to an advisory released Tuesday by the US Centers for Disease Control and Prevention.
“Recent case reports document that some patients with a normal immune response who have taken a five-day course of Paxlovid for a laboratory-confirmed infection and have recovered may experience recurrent disease two to eight days later, including patients who have been vaccinated and/or boosted,” the CDC advisory said.
In these cases of “COVID-19 rebound“, the disease improved or resolved in an average of three days, without additional anti-COVID treatment, the CDC said.
A relapse after treatment with Paxlovid does not mean the antiviral is not working, the advisory adds.
“A brief return of symptoms may be part of the natural history of SARS-CoV-2 (the virus that causes COVID-19) in some people, regardless of Paxlovid treatment and regardless of vaccination status,” the CDC said.
The agency added that “Paxlovid continues to be recommended for the early-stage treatment of mild to moderate COVID-19 in people at high risk of progression to severe disease.”
In clinical trials for Paxlovidsuch a rebound has been seen in some people who were in the placebo group and did not receive the drug, noted Dr. Amesh Adalja, principal investigator at the Johns Hopkins Center for Health Security in Baltimore.
In the original study, virus levels rose after 10 days in 1 to 2 percent of those taking the drug or placebo pills, noted Pfizer and the U.S. Food and Drug Administration.
“It is not known how common the rebound phenomenon of COVID-19 is, whether it is a natural progression of the disease in some individuals, what this relationship with Paxlovid and what’s behind it,” Adalja said.
He added that people with COVID rebound “did not have severe illness” but should self-isolate to protect others.
“People should be alert for a rebound in symptoms and test themselves and assume contagiousness if they test positive,” Adalja said.
The United States Centers for Disease Control and Prevention know more about COVID-19[feminine].
SOURCES: US Centers for Disease Control and Prevention, statement, May 24, 2022; Amesh Adalja, MD, Principal Investigator, Johns Hopkins Center for Health Security, Baltimore
By Dennis Thompson Health Day Reporter
Copyright © 2021 Health Day. All rights reserved.